Loading…
Rural Health Care Access Review Act of 2020
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,086 other S bills in the 116th — cohort avg 30d
Rural Health Care Access Review Act of 2020 This bill requires the Government Accountability Office to conduct a study on access to health care in rural areas during the COVID-19 (i.e., coronavirus disease 2019) emergency. Specifically, this study must evaluate the use of telehealth and the impact of enforcement discretion in the application of federal privacy standards for the use and disclosure of personal health information by health care providers, health plans, health clearinghouses, and their businesses associates.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2023 · third_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418/S. 1844, Animal Drug User Fee Amendments of 2023 H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 H.R. 4895, Lowering Drug Costs for American Families Act H.R. 5376/S. 2474, Share the Savings with Seniors Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Anti-microbial Resistance; Vaccines; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2023 Budget and Appropriations Legislation; Intellectual property protection and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; Animal Drug User Fee Reauthorization; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues Pharmacy Benefit Manager reforms.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $2,130,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · second_quarter · Health Issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021 H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418/S. 1844, Animal Drug User Fee Amendments of 2023 H.R. 1503/S. 1844, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2679, Pharmacy Benefits Manager Accountability Act H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880, Protecting Patients Against PBM Abuses Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023 H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3285, Fairness for Patient Medications Act H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Anti-microbial Resistance; Vaccines; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability; Animal Drug User Fee Reauthorization; One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Accelerated approval reform; Pharmacy Benefit Manager (PBM) policy issues.
Client expense: $2,980,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
H.R. 830, Help Ensure Lower Patient (HELP) Copays Act H.R. 1418, Animal Drug User Fee Amendments of 2023 H.R. 1503, Prescription Information Modernization Act of 2023 H.R. 1550, (117th Cong.) PREVENT HPV Cancers Act of 2021 H.R. 2873, (117th Cong.) Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3932/S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1712, (116th Cong.) Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2076, (117th Cong.) Pioneering Antimicrobial Subscriptions To End Up surging Resistance Act of 2021 or the PASTEUR Act of 2021 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, (117th Cong) Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 S. 4760, (116th Congress) The PASTEUR Act Issues relating to: 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccines issues; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Drug shortage issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Prescription drug cost-sharing; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; Intellectual property and trade issues; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; WTO IP Waiver for COVID therapeutics Animal Health; Animal Health Technology Issues; Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability One Health Issues; General pharmaceutical issues; Farm Bill 2023; Vaccine Injury Compensation Program (VICP); Step therapy requirements in commercial health plans; Diversity in clinical trials; Pharmacy Benefit Manager (PBM) policy issues.
Client expense: $2,930,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · fourth_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3655, Vaccine Injury Compensation Modernization Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 S. 4760, (116th Congress) The PASTEUR Act Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel issues; Prescription Drug User Fees Act (P.L. 102-571); Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions; Animal Drug User Fee Act (P.L. 108-130); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023 Vaccine Injury Compensation Program.
Client expense: $2,490,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · third_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Inflation Reduction Act of 2022, including provisions relating to drug pricing H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $1,080,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2022 · second_quarter · Health Issues
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act H.R. 19 Lower Costs, More Cures Act of 2021 H.R. 1550, PREVENT HPV Cancers Act of 2021 H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 3173, Improving Seniors Timely Access to Care Act of 2021 H.R. 3932/S. 2079, Pioneering Antimicrobial Subscriptions To End Up surging Resistance (PASTEUR) Act of 2021 H.R. 4127, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2021 H.R. 5260, Reduced Costs and Continued Cures Act H.R. 5376, Build Back Better Act H.R. 5416, Give Kids a Chance Act H.R. 5801, Help Ensure Lower Patient (HELP) Copays Act H.R. 6584, Diverse and Equitable Participation in Clinical Trials (DEPICT) Act H.R. 6963, Accelerated Approval Integrity Act of 2022 H.R. 7559, Prescription Information Modernization Act of 2022 H.R. 7667, Food and Drug Amendments of 2022 S. 1435, Affordable Prescriptions for Patients Act of 2021 S. 1712, Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act of 2019 S. 2774, Pride in Patent Ownership Act S. 2891, Restoring the America Invents Act S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019 S. 1895 (116th Congress) Lower Health Care Costs Act S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B policy; 340B issues; 340B drug pricing program; Drug pricing; Drug Pricing reforms - international reference prices and government price setting; Anti-microbial Resistance; Vaccines; COVID-19 vaccines; COVID-19 therapeutics coverage issues; COVID-19 Pandemic response; Cost and value of medicines; Respiratory Syncytial Virus (RSV) immunization; Vaccines catch up; Vaccine provisions; Vaccine Issues, including return to care access, and pandemic-related policy; Package inserts, labeling issues, and E-Labeling authorization legislation; Pharmaceutical Supply Channel Isssues; Prescription Drug User Fees Act (P.L. 102-571); Prescription drug cost-sharing; Accelerated approval reform; Food and Drug Administration Safety and Landmark Advancements (FDASLA); Executive Order 13937, Access to Affordable Life-Saving Medications; FY-2023 Budget and Appropriations Legislation; Intellectual property protection; WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Animal Health; Animal Health Technology Issues; One Health Issues; Rural Broadband Issues; General pharmaceutical issues; Farm Bill 2023; Animal Drug User Fee Act 2023.
Client expense: $2,610,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office